These results indicated that ANXA2 expression was closely corelated with the malignant biological process of glioma, and patients with higher levels of ANXA2 expression have a greater risk of tumor recurrence, progression, and therapeutic resistance than other patients. This evidence concerns the gene ANXA2 and neoplasm.